Introducion. Balloon aoric valvuloplasty (BAV) is a percutaneous treatment opion for aoric stenosis (AS). Because of early restenosis and poor long-term survival, it is used as a bridge to surgery (SAVR) or transcatheter aoric valve replacement (TAVR), in hemodinamically unstable paients or paients that require urgent non-cardiac surgery. Aim. The aim of this study was to evaluate all the BAV procedures performed in our centre in 2010 and to report our experience with BAV as a potenial bridge to deiniive therapy or as a palliaive treatment. Methods. We retrospecively analyzed all the paients who underwent percutaneous treatment of aoric stenosis in our insituion between January and December 2010. We straiied our cohort into 3 groups: BAV as a bridge to TAVR or SAVR, BAV as a inal therapy and TAVR without prior BAV. We evaluated paient characterisics, echocardiographic data and peri-procedural complicaions in each cohort. Survival was evaluated using Kaplan-Meier analysis. Results. We included 86 high risk symptomaic paients with mean age of 82.2 ± 5.0 years and mean logisic EuroSCORE of 19.2 ± 11.8 %. Ater BAV we observed a signiicant decrease in mean transvalvular gradient (from 43.8 ± 14.4 to 33.5 ± 12.3 mmHg; p < 0.01) and a signiicant increase in aoric valve area ater BAV (from 0.6 ± 0.2 to 0.8 ± 0.3 cm 2 ; p < 0.01). Systolic pulmonary artery pressure, let ventricular ejecion fracion and mitral regurgitaion did not change signiicantly. Major intrahospital complicaions occurred in 5 paients (6.5 %), without any death related to the procedure. BAV as a bridge to TAVR had a beter outcome compared with BAV alone. Conclusion. BAV is a feasible and reasonably safe approach for temporary relief of symptoms, improvement of quality of life, decrease of surgical risk prior major non-cardiac surgery or as a bridge to surgical or transcatheter aoric valve implantaion in severe aoric stenosis.
Introducion c alciic stenosis of the aoric valve (AS) is the most common acquired valve disorder in the Western world 1 . Surgical aoric valve replacement (SAVR) is considered the treatment of choice in paients with symptomaic AS regardless of age 2, 3 . The surgical risk in elderly paients with muliple comorbidiies may be high and the presence of concomitant coronary artery disease (CAD) with the need for addiional coronary artery bypass may duplicate the risk 4-6 . Balloon aoric valvuloplasty (BAV) was introduced in 1986 as the irst less invasive percutaneous treatment opion of symptomaic AS 7 . Unfortunately, early restenosis of the dilated valve with symptoms recurrence and poor long-term survival limits the use of this procedure [8] [9] [10] [11] [12] . Today BAV may be considered as a bridge to surgery or percutaneous aoric valve replacement (TA-VR) in haemodynamic unstable paients or paients that require urgent major non-cardiac surgery. Balloon valvuloplasty may also be considered as a palliative measure in selected individual cases when surgery is contraindicated because of severe comorbidiies and when TAVR is not an opion 13 .
Percutaneous aoric valve treatment program started in our medical centre in 2008 as a part of preparaion for TAVR program. BAV was not frequently used in our centre before. Since 2008 we performed over 330 BAV procedures and 110 TAVR implantaions. The present study evaluated all the BAV procedures we performed in 2010 and reports our experience with BAV in symptomaic high risk paients with severe aoric stenosis, as a potenial bridge to deiniive therapy or as a palliaive treatment.
Methods

Paient populaion and selecion
We retrospecively analyzed all the paients who underwent percutaneous treatment of aoric stenosis in our insituion between January and December 2010. We straiied our cohort into 3 groups according to the Srce i krvni sudovi 2014; 33(1): 21-26 inal treatment: BAV as a bridge to TAVR or SAVR, BAV as a inal therapy (including repeated BAV) and TAVR without prior BAV.
Criteria for BAV and/or TAVR included: -symptomaic aoric stenosis conirmed by transthoracic echocardiography with aoric valve area < 1 cm 2 (< 0.6 cm 2 /m 2 ), -operaive risk esimated by logisic EuroSCORE (European System of Cardiac Operaive Risk Evaluaion) > 15 %, -contra-indicaion for surgery because of comorbid condiions; assessed and agreed to by both an independent cardiologist and a cardiovascular surgeon.
Criteria for BAV as a bridge to TAVR or SAVR included:
hemodynamic unstable paient, -prior urgent major non-cardiac surgery (for example paients with carcinoma),
mitral regurgitaion (MR) > 2+, -pulmonary hypertension due to combinaion of COPB and let ventricular failure.
Echocardiographic data
The screening before and ater the percutaneous procedure included transthoracic echocardiography (TTE) recording of aoric stenosis severity, aoric valve regurgitaion, let ventricular funcion, addiional mitral regurgitaion and pulmonary artery systolic pressure.
BAV procedure
The procedures were performed in our cardiac catheterisaion laboratory in local anesthesia. Paients selected for BAV underwent diagnosic right and let cardiac catheterizaion. In case of coronary artery disease an angioplasty was performed before BAV in the same intervenion. Heparin (70UI/kg) was administered ater 10F sheath inserion in the femoral artery and pig tail through 5F sheet in radial artery. Aoric valve was crossed by LA1 catheter (Cordis) and J wire. J.wire was subsituted for supporive Amplatz sif wire (Abbot). Via percutaneous trans-femoral approach a balloon catheter (Zelos, Op-iMed, 18-25 mm x 4.0 cm) was introduced and posiioned across the stenoic aoric valve. We used undersized dilatation balloons according to TTE annulus diameter. Aoric valvuloplasty was performed with balloon inlaion (25-30 ml, burst rate 4 ATM). Selecion of the balloon inlaion size was based on the combinaion of transthoracic echocardiography, baseline aortography, and alignment of the balloon to aoric annulus during valvuloplasty balloon expansion. To stabilize the balloon posiion across the valve, rapid ventricular pacing (180-220 beats/min) was done during each inlaion using temporary pacemaker electrode inserted in right ventricle through femoral vein. Before and ater the valvuloplasty peak to peak pressure gradient was measure with pigtail catheters into aorta and let ventricle. The goal of the procedure was a reducion of the gradient by at least 50% and if necessary, the balloon inlaion was repeated. In case of irst BAV balloon under-sizing the second BAV was performed with the next, bigger sized balloon. Hemostasis was performed with vascular closure devices Pro-glide (Abbot vascular) or with direct manual compression of radial and femoral arterial puncture site ad once and ater 3-4 hours, respecively.
TAVR procedure
The selecion of TAVR candidates was done according to Edwards recommendaions. All the paients were refused for classic AVR. Indicaion for TAVR was also condiioned by TAV availability. We used Edwards-Sapien devices. Sizing was done by combinaion of CTA and TEE. Implantaions were performed in coronary cathlab in sterile regimen. TAVI team members (anaestheist, cardiovascular surgeon, intervenional cardiologists, ECHO specialists) paricipated in the paients selecion. Paients were operated in general anesthesia. Both trans-apical and trans-femoral TAVR approaches were uilized.
Data collecion and follow up
Baseline clinical data were retrospecively collected from the medical records. Logisic EuroSCORE was calculated for all paients based on baseline variables before the procedure. All clinically relevant baseline and follow-up variables as well as peri-procedural complicaion were prospecively entered into a dedicated database. In-hospital follow-up consisted of vital parameters, complete blood count and assessment of renal funcion, review of arterial puncture site and TTE within few days ater BAV. Clinical and echocardiographic follow up was planned at 3 to 6 months ater BAV and obtained from chart review.
Major peri-procedural adverse events were deined as peri-procedural death from any cause, myocardial infarcion, severe acute aoric regurgitaion, stroke, cardiac tamponade, cardiogenic shock, aoric dissecion, major vascular complicaions, urgent or emergency conversion to surgery or permanent pacemaker requirement. Acute renal impairment, myocardial infarcion, stroke, vascular complicaions and major bleeding were deined according to the Valve Academic Research Consorium proposed criteria (VARC) 14 .
Staisical analysis
Qualitaive variables were expressed as percentages and quanitaive variables were expressed as mean ± standard deviaion. Comparison of coninuous variables was performed with the analysis of variance and Student's paired t-test, as appropriate. The χ2 test was used to compare qualitaive variables. Survival rates were presented as Kaplan-Meier curves, and the log-rank test was used for comparison. Diferences were considered staisically signiicant at P < 0.05. All data were processed using the Staisical Package for Social Sciences, version 17.0 (SPSS, Inc., Chicago, Illinois).
Results
The cohort included 86 consecuive paients who underwent percutaneous treatment of severe aoric stenosis in 2010 in our insituion. BAV was performed in 77 paients (89.5 %), followed by TAVR in 19 paients (22.1 %) and SAVR in one paient (1.2 %). Nine paients (10.5 %) underwent TAVR without previous BAV procedure.
Baseline characterisics
The baseline characterisics of all paients are displayed in the Table 1 . They all had symptomaic severe aoric stenosis with mean AVA of 0.6 ± 0.2 cm 2 and were at high risk for surgical valve replacement. All the paients were older than 80 years with the mean age of 82.2 ± 5.0 years, mean logisic EuroSCORE of 19.2 ± 11.8 and 54 (62.8 %) of them were presening in New Your Heart Associaion (NYHA) class III/IV. 
Indicaions for BAV
Hemodynamic results
After BAV we observed a significant decrease in mean trans-valvular gradient (from 43.8 ± 14.4 to 33.5 ± 12.3 mm Hg; p < 0.01) and an signiicant increase in aoric valve area (from 0.6 ± 0.2 to 0.8 ± 0.3 cm 2 ; p < 0.01). Procedural success was achieved in 73% of paients (reducion of peak to peak gradient on half), however 84% of paients improved clinically with reducion of pulmonary and right side congesion. Systolic pulmonary artery pressure, let ventricular ejecion fracion and mitral regurgitaion did not signiicantly change ater BAV. 
Procedural complicaions
Complications related to BAV are summarized in Table 2 . Major intra-hospital complicaions occurred in 5 paients (6.5 %). We did not observe any death related to the BAV procedure. One paient died few days ater BAV because of cardiogenic shock developed before the procedure. Major vascular complicaion occurred in 4 paients (5.2 %) where we observed pseudo-aneurysm leading to unplanned surgical intervenion. Other vascular complicaions were classiied as minor in 11 pa- ients (14.3 %) -need for blood transfusion and pseudoaneurysm (2 cases) with no need for vascular surgery. In one paient we observed iodinated contrast induced thyrotoxicosis which was successfully treated with thyreo-staic drugs. The most common complicaion was related to vascular access site. Acute myocardial infarcion occurred in one case (1.3 %) and acute renal injury in 3 cases (4 %). We did not observe severe aoric regurgitaion, stroke, permanent pacemaker requirement, tamponade or anular rupture in our paients.
Follow up and mortality
Paients let hospital 13.4 ± 10.8 days ater BAV. 92% of the paients were in follow up of 16.1 ± 15.0 months. Within this period 20 paients were inally bridged to deiniive therapy [TAVR n = 19 (22.1 %) and SAVR n = 1 (1.2 %)] and 66 (76.7 %) unsuitable for deiniive therapy remained on medical therapy alone. In four paients BAV was repeated once and in two paients BAV twice during the follow up period. In 14 cases with concomitant coronary artery disease we performed BAV and PCI in a single procedure with no increase in peri-procedural complicaion rate. In 3 oncologic paients with severe aoric stenosis that required a major abdominal and gynecology surgery BAV and in one case BAV and PCI was done prior surgery. With angioplasty and BAV we achieved a good coronary artery low and an increase in aoric valve area without any peri-procedural complicaions. Successful non-cardiac surgery was consecuively done in all the 3 cases 15 .
Baseline characterisics of paients according to inal treatment ater BAV are presented in Table 3 and compared with the characterisics of paients who underwent Results presented as mean ± standard deviaion/ number (%).
* p value related to the comparison of the group that underwent BAV versus the group that underwent TAVR ater BAV. Abbreviaions: TAVR: transcatheter aoric valve replacement; TAVR only: TAVR paients without prior BAV; PCI: percutaneous coronary intervenion; NYHA: New York Heart Associaion; COPD: chronic obstrucive pulmonary disease; PAOD: peripheral arterial occlusive disease; AVA: aoric valve area; LVEF: let ventricular ejecion fracion.
TAVR without previous BAV procedure. Overall, paients who underwent TAVR without previous BAV were less symptomaic and presented in lower NYHA funcional class. There were no diferences in AVA, mean trans-aoric gradient, pulmonary artery arterial pressure and mitral regurgitaion severity between groups (Table 3) . Long-term follow-up was evaluated using Kaplan-Meier analysis, and survival curves according to treatment ater BAV are shown in Figure 2 . Paient bridged to TAVR had better outcomes compared with those treated by single BAV (p < 0.01). There was no signiicant impact on survival in paients where BAV was performed more than once and in paients where TAVR was performed without previous BAV (Figure 2-4 ).
Discussion
BAV was originally proposed as an alternaive to SAVR for severe symptomaic AS, but it was rapidly neglected secondary to high restenosis rates and no impact on survival. In the TAVR era BAV was reported to be inferior to TAVR and comparable to medical therapy in terms of survival (16) . We can conirm that single BAV, without bridge to TAVR/SAVR is associated to bad outcome. However, BAV might be a reasonable approach to ofer symptomaic relief and improvement of the quality of life in selected high risk, comorbid paients and paients with short life expectancy. Current guidelines support this statement (recommendaion Class IIb) and suggest this per-cutaneous treatment also as a bridge to TAVR/SAVR in hemodynamic unstable paients or in paients who require urgent major non-cardiac surgery (2, 17) .
BAV as a deiniion therapy
In our cohort of very high risk paients with aoric stenosis, BAV was associated with staisically signiicant hemodynamic results with signiicant decrease of mean aoric gradient in BAV, BAV-TAVR and TAVR group from: 46.5±14.3 mmHg, 35.7±10.5 mmHg, 42.6±8.8 mmHg to 35.5±13.8 mmHg, 40.0±14.2 mmHg and 11.5±2.1, respecively. The major indicaion for BAV remains symptomaic relief (61.0 %) and due to low major complicaion rate (6.5 %) it is a reasonable approach. Vascular access site complicaions remain the principal procedural limitaion but with the development of the technique over the years and with the use of vascular closure devices we may reduce the complicaion rate. In contrast to our experience, Eltchaninof et al., reported an increase of aoric valve area > 1 cm 2 ater BAV in most of the paients, recently (18) . From this perspecive, BAV may become a valid therapeuic opion for high risk paients refused for surgery and unsuitable for TAVR. In our case AVA improved from 0.6 ± 0.2 to 0.8 ± 0.3 cm 2 ; p < 0.01. One of the reasons for less efecive BAV comparing to the results published by Eltchaninof et al. might be our conservaive strategy. Namely, BAV is rather palliaive procedure, therefore we were using undersized balloons for non-aggressive BAV. The rate of important AR and annulus damage is therefore zero. Most frequently we used BAV balloon of dimensions 20 mm, 23 mm and 25 mm in 78%, 18% and 4%, respecively. 
BAV as a bridge to TAVR/SARV
Soon ater BAV we oten observe an improvement of hemodynamic condiions; an increase of cardiac output, a reducion of pulmonary pressure and improvement of other heart failure clinical presentaions (16) . As a consequence BAV is recommended as a bridge to TAVR/SAVR in hemodynamic instable paients sufering from a potenially reversible acute state (for example sepsis or cardiogenic shock) (13) . In our cohort we performed BAV in one paient (1.3 %) who presented in cardiogenic shock but despite the successful procedure he died because of the underlying disease. BAV may be also performed in paients who are good candidates for TAVR but per-cutaneous valve implantaion is not available because of the economical and organisaional issues. In potenial TAVR candidates BAV can also serve as a diagnosic measure, which can help deine the inal therapeuic opion: BAV or TAVR. In paricular it can be used to asses the potenial impact of let ventricular aterload reducion on improvement of low let ventricular ejecion fracion, severe pulmonary hypertension and mitral regurgitaion improvement.
BAV in cancer paients
We performed BAV in three oncologic paients that underwent major abdominal surgery soon ater the percutaneous aoric procedure. Successful BAV and hemodynamic improvement should decrease the risk for abdominal surgery. In our experience the surgery was performed without cardiovascular complications. In selected high risk carcinoma paients BAV may be used as bridge to TAVI which can be done if there is no carcinoma relapse one year ater non-cardiac surgery.
Long-term outcome ater BAV
According to the results of PARTNER trial (16) we demonstrated that BAV remain a palliaive measure, with no impact on long-term survival. The survival in patients bridged to TAVR after BAV was significantly higher than in those treated with BAV alone. In paients where BAV was performed more than once in comparison to single BAV we observe a trend of beter outcome that is not staisically signiicant. We can speculate that early restenosis of the dilated aoric valve and consecuive relaively rapid re-increase in let ventricular aterload prevent ventricular reverse remodelling and exhibit the posiive impact on the let ventricle we achieved early ater BAV. With prevenion of restenosis we may ind a way to improve the outcome ater BAV but unil now no treatment strategy succeed in this atempt (20).
Conclusion
In conclusion, BAV is a feasible and reasonably safe approach to ofer temporary relief in selected high risk paients with symptomaic severe aoric. BAV can be uilized as a part of a complex to improve the quality of life, decrease the surgical risk for major non-cardiac surgery or as a bridge to surgical or trans-catheter aoric valve implantaion. BAV can also be used to select the best further treatment strategy (TAVR/SAVR or medical therapy) in paients with impaired LV funcion, pulmonary hypertension and important mitral regurgitaion.
